Who is sponsoring NCT04317287?

NCT04317287 is sponsored by Supplement Formulators, Inc..

What drugs are being tested in NCT04317287?

Interventions in NCT04317287: Cardio formulation, Placebo.

What condition does NCT04317287 study?

NCT04317287 studies Oxidized Low Density Lipoprotein.

Is NCT04317287 still recruiting?

NCT04317287 is currently terminated. Last updated 13 January 2023.

Last reviewed 2023-01-13 · How we verify

NCT04317287

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Assess the Efficacy and Safety of the Cardio Formulation in Reducing Oxidized LDL

Terminated NA Last updated 13 January 2023

What this trial tests

NA trial testing Cardio formulation in Oxidized Low Density Lipoprotein in 9 participants. Terminated before completion.

Timeline

10 December 2019

Primary endpoint
19 November 2021

19 November 2021

Quick facts

Lead sponsor	Supplement Formulators, Inc.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	9
Start date	10 December 2019
Primary completion	19 November 2021
Estimated completion	19 November 2021
Sites	1 location across United States

Drugs / interventions tested

Cardio formulation
Placebo

Conditions studied

Oxidized Low Density Lipoprotein — all drugs for Oxidized Low Density Lipoprotein →

Sponsor

Supplement Formulators, Inc.

Who can join

Adults 40 to 75, any sex, with Oxidized Low Density Lipoprotein. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the efficacy and safety of the Cardio formulation in reducing oxidized LDL \[(Ox LDL (low density lipoprotein)\] in overweight to mildly obese generally healthy adults.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Supplement Formulators, Inc. trials

Trials by the same sponsor.

NCT07371975 — A Study to Evaluate the Effects of a Butyrate-Polyphenol Formulation on Gut Health and Associated Symptoms · NA · recruiting
NCT06419231 — Effectiveness of a Butyrate Formulation and Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated · NA · completed
NCT05854017 — Effects of a Theanine for Stress Relief Formulation in Individuals Who Report Occasional Moderate High Levels of Stress. · NA · active not recruiting
NCT05450952 — Evaluate the Effects of a Theanine Formulation on Stress, Burnout, Mood, and Sleep in Individuals Who Report Occasional · NA · terminated
NCT05170113 — Evaluate the Effectiveness and Safety of the Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulatio · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04317287 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Supplement Formulators, Inc.
Last refreshed: 13 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04317287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing